Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Treasury Shares: 2016-2025

Historic Treasury Shares for Ultragenyx Pharmaceutical (RARE) over the last 3 years, with Sep 2025 value amounting to $8.0 million.

  • Ultragenyx Pharmaceutical's Treasury Shares rose 124.78% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 124.78%. This contributed to the annual value of $3.6 million for FY2024, which is 731.71% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Treasury Shares stood at $173,034 for Q3 2025, which was down 0.00% from $173,034 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Treasury Shares high stood at $1.7 million for Q4 2021, and its period low was $7,812 during Q1 2023.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Treasury Shares value was $65,063 (recorded in 2024), while the average stood at $73,635.
  • Data for Ultragenyx Pharmaceutical's Treasury Shares shows a peak YoY soared of 835.96% (in 2024) over the last 5 years.
  • Over the past 3 years, Ultragenyx Pharmaceutical's Treasury Shares (Quarterly) stood at $432,000 in 2023, then spiked by 731.71% to $3.6 million in 2024, then soared by 124.78% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $8.0 million for Q2 2025, and $7.6 million during Q1 2025.